3,4-di-hydrocinnamante derivatives (KRIBB)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Name3,4-di-hydrocinnamante derivatives (KRIBB)
Drug Alias Name3,4-di(OH)-hydrocinnamatedihydrocaffeateE-040E-076E-030
ClassificationSmall molecules
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHyperlipidemiasAtherosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKorean Research Institute of Bioscience and Biotechnology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKorean Research Institute of Bioscience and Biotechnology
Active IndicationsN/A
Inactive IndicationsHyperlipidemiasAtherosclerosis

Other Information

ATC CodeN/A
Related LinksN/A